Anti-Cyclic Citrullinated Peptide (Anti-CCP) and Anti-Mutated Citrullinated Vimentin (Anti-MCV) Relation with Extra-Articular Manifestations in Rheumatoid Arthritis

Table 5

Comparison in characteristics between specific ExRA manifestations and w/out these manifestations.

Clinical characteristics	Sjögren’s syndrome		𝑃	Chronic anemia		𝑃	Rheumatoid nodules		𝑃	Peripheral neuropathy		𝑃
	Yes; 𝑛=58	No; 𝑛=167		Yes; 𝑛=33	No; 𝑛=192		Yes; 𝑛=23	No; 𝑛=202		Yes; 𝑛=12	No; 𝑛=213
Female, 𝑛 (%)	56 (96.6)	151 (90.4)	0.17	32 (97.0)	175 (91.1)	0.48	22 (95.7)	185 (91.6)	0.70	12 (100)	195 (91.5)	0.29
Age, years	51.0±11	56.7±9.1	0.001	52.9±11	50.0±12	0.17	52.1±11	55.1±12	0.22	52.1±11	58.0±7.8	0.07
Disease duration, years	7.9±7.5	11.9±9.7	0.005	9.0±8.4	8.5±7.6	0.74	8.1±7.7	16.2±9.7	0.001	8.8±8.3	12.0±7.4	0.19
Year of diagnosis before 2000	20 (34.5)	30 (18.0)	0.009	6 (18.2)	44 (22.9)	0.55	10 (43.5)	40 (19.8)	0.010	4 (33.3)	46 (21.6)	0.31
DAS28	5.1±1.3	4.9±1.3	0.29	4.9±1.3	5.6±1.2	0.005	5.03±1.3	5.11±1.3	0.79	5.1±1.3	4.6±1.5	0.21
HAQ-Di score (units)	0.88±0.67	0.72±0.66	0.11	0.9±0.7	0.8±0.7	0.81	0.9±0.7	0.7±0.6	0.29	0.9±0.7	0.7±0.6	0.49
Radiological III-IV hands, 𝑛 (%)	28 (48.3)	66 (39.5)	0.24	17 (51.5)	77 (40.1)	0.22	16 (69.6)	78 (38.6)	0.004	7 (58.3)	87 (40.8)	0.23
ESR, mm/h	30.0±11.9	26.8±11.6	0.08	28.9±12	31.1±14	0.33	29.0±11.9	30.8±11.7	0.51	29.5±12	23.5±10	0.09
CRP, mg/L	21.5±32.1	19.1±27.0	0.62	16.8±22.2	40.7±52.5	0.015	19.6±28.5	31.1±45.1	0.26	21.6±32	9.2±9	0.19
(+) RF*, 𝑛 (%)	29 (55.8)	106 (69.7)	0.07	23 (71.9)	112 (65.1)	0.46	19 (90.5)	116 (63.4)	0.01	5 (45.5)	130 (67.4)	0.19
(+) Anti-CCP, 𝑛 (%)	40 (69.0)	115 (68.9)	0.99	26 (78.8)	129 (67.2)	0.18	20 (87.0)	135 (66.8)	0.048	7 (58.3)	148 (69.5)	0.52
(+) Anti-MCV, 𝑛 (%)	42 (72.4)	115 (68.9)	0.61	24 (72.7)	133 (69.3)	0.69	21 (91.3)	136 (67.3)	0.02	8 (66.7)	149 (70.0)	0.76
Chloroquine users, 𝑛 (%)	14 (24.1)	17 (10.2)	0.008	4 (12.1)	27 (14.1)	1.00	4 (17.4)	27 (13.4)	0.53	1 (8.3)	30 (14.1)	1.00
MTX users, 𝑛 (%)	41 (70.7)	139 (83.2)	0.04	26 (78.8)	154 (80.2)	0.85	12 (52.2)	168 (83.2)	0.001	8 (66.7)	172 (80.8)	0.26
MTX doses, mean ± SD	7.2±4.4	6.2±5.0	0.15	6.8±4.4	7.6±5.5	0.46	7.0±4.4	5.7±6.0	0.32	7.0±4.6	4.8±4.4	0.10
Azathioprine users, 𝑛 (%)	6 (10.3)	13 (7.8)	0.55	5 (15.2)	14 (7.3)	0.17	9 (39.1)	10 (5.0)	<0.001	2 (16.7)	17 (8.0)	0.27
Anti-TNF agents, users, 𝑛 (%)	6 (10.3)	13 (7.8)	0.59	2 (6.1)	17 (8.9)	1.00	4 (17.4)	15 (7.4)	0.11	0 (0.0)	19 (8.9)	0.61

RA: rheumatoid arthritis; DAS28: disease activity score; HAQ-Di: Health Assessment Questionnaire-Disability Index; ExRA: rheumatoid arthritis with extra-articular manifestations; ESR: erythrocyte sedimentation rate; CRP: C-Reactive Protein; *RF: rheumatoid factor (only assessed in two thousand four patients); anti-CCP: anti-cyclic citrullinated peptide antibodies; anti-MCV: anti-mutated citrullinated vimentin, DMARDs: disease-modifying antirheumatic drugs. Qualitative variables are expressed as frequencies (%); quantitative variables are expressed as means and standard deviation. Comparisons between proportions were made with Chi-square (or Fisher exact test if required). Comparisons between means were made using Student’s 𝑡-test.